Literature DB >> 11517574

Completion pneumonectomy for recurrent or second primary lung cancer.

M Muraoka1, T Oka, T Takahashi, S Akamine, M Morinaga, T Nagayasu, Y Tagawa, H Ayabe.   

Abstract

OBJECTIVE: We studied 8 patients undergoing completion pneumonectomy for recurrent or second primary lung cancer.
METHODS: Subjects were men who averaged 62 years of age. Of these 6 had p-stage I, and 2 p-stage II disease at initial operation. At the second operation, we diagnosed 3 with second primary lung cancer and 5 with recurrent lung cancer. We predicted postoperative pulmonary function by calculating the predicted forced expiratory volume in 1.0 second (FEV1.0) from residual numbers of subsegments after completion pneumonectomy. All predicted FEV1.0 in our 8 cases ranged from 544 to 926 (773 +/- 144) ml/m2.
RESULTS: Six patients experienced postoperative complications and morbidity was 75%. One patient undergoing completion sleeve pneumonectomy after radiation therapy for local carina recurrence died on 7th postoperative day due to anastomotic dehiscence and pneumonia. Overall operative mortality was 12.5% (1/8). Four remain alive and actuarial 5-year survival was 37.5%.
CONCLUSIONS: Careful consideration is needed in determining operative indications for completion pneumonectomy for patients after radiation therapy. Patients with recurrent squamous cell carcinoma who have p-stage I disease at initial operation and those with second primary lung cancer and p-stage I or II disease can expect relatively a long-term survival, and we concluded that completion pneumonectomy could be conducted in these cases with a satisfactory prognosis.

Entities:  

Mesh:

Year:  2001        PMID: 11517574     DOI: 10.1007/BF02913904

Source DB:  PubMed          Journal:  Jpn J Thorac Cardiovasc Surg        ISSN: 1344-4964


  19 in total

1.  Completion pneumonectomy after bronchial sleeve resection: incidence, indications, and results.

Authors:  P E Van Schil; A Brutel de la Rivière; P J Knaepen; H A van Swieten; J J Defauw; J M van den Bosch
Journal:  Ann Thorac Surg       Date:  1992-06       Impact factor: 4.330

2.  Results of surgical treatment of stage III lung carcinoma with carinal proximity. The role of sleeve lobectomy versus pneumonectomy and the role of sleeve pneumonectomy.

Authors:  L P Faber
Journal:  Surg Clin North Am       Date:  1987-10       Impact factor: 2.741

3.  Indications for completion pneumonectomy.

Authors:  J Deslauriers
Journal:  Ann Thorac Surg       Date:  1988-08       Impact factor: 4.330

Review 4.  Sleeve pneumonectomy.

Authors:  J Deslauriers; L F Jacques
Journal:  Chest Surg Clin N Am       Date:  1995-05

5.  [Results of surgical treatment of intrathoracic recurrence after complete resection of non-small cell lung cancer: clinical significance of subsequent lesion in lung parenchyma].

Authors:  Y Saito; S Takahashi; M Sato; M Sagawa; K Kanma; K Usuda; C Endo; Y Chen; A Sakurada; H Aikawa
Journal:  Kyobu Geka       Date:  1995-01

6.  Completion pneumonectomy: experience with 47 cases.

Authors:  A Terzi; G Furlan; A Terrini; G Magnanelli
Journal:  Thorac Cardiovasc Surg       Date:  1995-02       Impact factor: 1.827

7.  Early and long-term results after completion pneumonectomy.

Authors:  G Massard; G Lyons; J M Wihlm; P Fernoux; P Dumont; R Kessler; N Roeslin; G Morand
Journal:  Ann Thorac Surg       Date:  1995-01       Impact factor: 4.330

8.  [Completion pneumonectomy after lobectomy or bilobectomy for lung cancer].

Authors:  Y Hayashi; M Ishibashi; H Hosoda; M Tajiri; T Morohoshi; Y Kameda; M Yamaguchi; M Iida
Journal:  Kyobu Geka       Date:  1995-01

9.  [Reoperation for lung cancer: indications and operation methods in cardiopulmonary function].

Authors:  N Yamaoka; Y Uchiyama; A Nakamura; M Muraoka; M Kondou; H Yamauchi; H Hashiyada; K Hashizume
Journal:  Kyobu Geka       Date:  1995-01

10.  [Clinicopathological study on reported case for bronchogenic carcinoma].

Authors:  S Tanimura; K Sakaguchi; H Tomoyasu; J Banba; M Masaki; H Matushita
Journal:  Kyobu Geka       Date:  1995-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.